International Clinical Trial: Neoadjuvant Chemotherapy Combined with PD-L1/VEGF Bispecific Antibody versus Combined with PD-1 Monoclonal Antibody in Locally Advanced Non-Small Cell Lung Cancer: A Multicenter, Randomized Controlled Clinical Trial

Geneva, May 18 -- International Clinical Trials Registry received information related to the study (ChiCTR2600124154) titled 'Neoadjuvant Chemotherapy Combined with PD-L1/VEGF Bispecific Antibody versus Combined with PD-1 Monoclonal Antibody in Locally Advanced Non-Small Cell Lung Cancer: A Multicenter, Randomized Controlled Clinical Trial' on May 8.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Shanghai Pulmonary Hospital

Condition: Non-small cell lung cancer

Intervention: Experimental Group:Neoadjuvant Phase: PD-L1/VEGF Bispecific Antibody: Intravenous administration, dose at RP2D, q3w for 3 cycles Platinum- plus taxane-based chemotherapy: q3w for 3 cycles. Local Treatment Phase: After 3 cycles, surgic...